Status:
ACTIVE_NOT_RECRUITING
Identifying the Neural Basis of Capability for Suicide
Lead Sponsor:
Unity Health Toronto
Conditions:
Major Depressive Disorder
Suicide
Eligibility:
All Genders
18-70 years
Brief Summary
Since capability for suicide involves overriding potential pain, and the opioid system plays a strong role in controlling pain perception, it follows that capability for suicide may be impacted by the...
Detailed Description
Little evidence exists distinguishing individuals with suicidal ideation (SI) from those at risk for suicidal behaviour, illustrating the need for more comprehensive biomarkers for clinicians to guide...
Eligibility Criteria
Inclusion
- Inclusion criteria for patients:
- Age between 18-70
- Capability of giving informed consent
- Not currently pregnant or lactating (due to potential confounding of brain activity as a result of differing hormone levels)
- Exclusion criteria for patients:
- Lifetime history of any substance abuse, psychosis
- Current use of any opioid acting drugs
- Current use of any prescription pain medication
- Use of over the counter pain medications within 15 hours of brain scan
- For daily users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 12 hours of brain scan
- For as needed users of a benzodiazepine, stimulant or atypical antipsychotic, dose within 2 weeks of brain scan. This is because non-daily use will have more unpredictable effects on brain imaging results than those who are using these medications on a regular basis. The 2 weeks will ensure the drug is not in the system.
- Medical condition requiring immediate investigation or treatment
- Participation in experimental treatment trials for the study duration.
- Healthy control inclusion criteria: Ages between 18 and 70 years, capable of giving informed consent, not pregnant or lactating, no lifetime history of Axis I/II disorders, no history of antidepressant or mood stabilizer use, no treatment for acute or ongoing medical condition, no use of any over the counter pain medication for at least 15 hours prior to the brain scan.
Exclusion
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03327129
Start Date
January 1 2023
End Date
September 1 2024
Last Update
August 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Michael's Hospital
Toronto, Ontario, Canada, M5B 0C1